American Association for Cancer Research

Continuing Medical Education (CME) Information


American Association for Cancer Research (AACR) is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education (CME) activities for physicians.


AACR has designated this educational activity for a maximum of 38.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.


It is the policy of AACR that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Program Committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. In addition, off-label and investigational uses will be identified when mentioned.


Advances in technology, progress in prevention, and exponential developments in the field of translational cancer medicine have increased the importance of fostering dynamic collaborations among basic researchers, physicians, and clinician-scientists. Bridging the gap between what physicians understand about cancer biology and its application to clinical oncology is critical to the implementation of the most current, approved molecular-based tests to aid in the diagnosis, treatment and prevention of cancer. Moreover, facilitating the interface between physicians and scientists will increase physicians’ knowledge of the epidemiological implications of cancer incidence and the contributions of laboratory research to drug development as well as patient care; transform the design and conduct of clinical research protocols; and, create a forum for the more rapid translation of laboratory research findings from “bench-to-bedside” for the benefit of improving patient outcomes.

    After participating in this CME activity, participants will be able to:
  1. Demonstrate a clear understanding of the latest research findings in all areas of cancer research and how these findings will impact future decision making in the detection, diagnosis, prognosis, treatment, and prevention of cancer;
  2. Translate how the integration of information from the basic, translational, and clinical sciences applies to the development of new drugs and clinical research trials;
  3. Employ technological advances to accelerate the research progress, improve early detection and screening options, which will ultimately extend patients’ lives and improve their quality of life;
  4. Integrate the use of molecular imaging and tumor profiling to more accurately predict cancer susceptibility, treatment strategies, as well as treatment outcomes;
  5. Evaluate the use of biomarkers and other indicators to improve patient selection (or stratification) for clinical trials in this era of personalized medicine; and,
  6. Formulate new strategies and forge collaborations that will further scientific and clinical research efforts towards the prevention, diagnosis, early detection, and treatment of cancer.


This AACR CME activity is supported by Medical Education Grants from Pfizer, Merck, Sanofi-Aventis, Genentech, Millennium, and Boehringer Ingelheim Pharmaceuticals.

For more information regarding this CME activity, please e-mail